This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Repros Reports Issuance Of Two Additional U.S. Androxal(R) Patents

  • Both patents cover the significant co-morbidity associated with low T and Type 2 diabetes
  • US patents 8,372,887 and 8,377,991 will expire in 2028 and 2031, respectively

THE WOODLANDS, Texas, April 10, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® (Nasdaq:RPRX) announced two patents representing potentially large commercial indications for its drug Androxal have been issued. The two patents deal with the metabolic consequences of low testosterone and the positive outcomes associated with restoration of testicular function exhibited by Androxal. The 8,377,991 patent specifically covers treatment of Type 2 diabetes, an area of high unmet medical need. The 991 issuance and patent life should have a positive impact on Androxal's long-term commercial potential.

The 991 patent is based on Repros' original findings from the Phase 2 study ZA-202. In study ZA-202, Repros investigated the potential of Androxal to improve glycemic control in Type 2 diabetic men currently being treated with oral hypoglycemic agents for their condition. That trial showed statistically significant improvement in HbA1c and insulin, as well as HOMA-IR compared to placebo in men < 55 years of age in the 3 month study. While the Company has an active IND open with the Division of Endocrine and Metabolic Products at the FDA, Repros has been focusing its efforts on the urological application of Androxal as well as the Proellex woman's health program for uterine fibroids and endometriosis.

Joseph S. Podolski, President and CEO of Repros commented, "The co-morbidity of Type 2 diabetes, low T and obesity is undeniable. The fact that several hormone replacement therapies have failed to show an impact on glycemic control, underscores the potential of Androxal. This restoration of organ function is a unique feature of Androxal compared to the approved hormone replacement therapies." He further noted, "Today the Endocrine Society recommends that physicians assess testosterone levels in men suspected to be Type 2 diabetic or pre-diabetic. Androxal offers a rational approach to treat the hypogonadal diabetic male. Endocrinologists represent a special population of readily reached physicians that may be the first adopters of Androxal in the treatment of hypogonadism."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.97 0.25%
FB $118.57 0.84%
GOOG $698.21 0.75%
TSLA $238.50 -0.94%
YHOO $36.53 -0.19%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs